Expertise, Role and Activity
IRTAL is a biotech SME founded in 2013 in Arezzo (Italy). The company specializes in two primary areas: clinical biomechanical testing in orthopaedics and sport injuries, and biological research focused on biomarkers for osteoarthritis and biomaterial development for bone regeneration. Leveraging its experience in biomaterial development and validation, IRTAL’s role in BactEradiX includes the biocompatibility evaluation of nanoplatform components (WP6, WP2, WP5) and the assessment of intellectual property rights (IPR) (WP8).
PI: Roberto Tiribuzi
Roberto Tiribuzi is a Biologist with a PhD in molecular Biotechnology and extensive expertise in biochemistry and cell biology. His recent research focuses on the development and characterisation of an osteoconductive liquid scaffold (Patent n° 102017000110258). In this project, he oversees the toxicology and biocompatibility assessment of nanoplatforms components (WP6, WP2, WP5) and managing intellectual property rights, with a particular focus on patent-related matters (WP8).
Cerulli Giuliano Giorgio
Giuliano Giorgio Cerulli is a full Professor of Orthopaedics and Traumatology. He brings extensive expertise in surgical procedures and related infection management. Previously, he served as a member of the National Health Council, focusing on the validation of medical devices. Within BactEradiX, he contributes to the biocompatibility assessment of the nanoplatform (WP6) and plays a key role in the communication, dissemination, and exploitation of results (WP7).
Francesca Cerulli
Francesca Cerulli holds a degree in Economics with a Master in “Business strategy” at Bocconi University. As an SME owner, she is responsible for both the management (WP1) and is a member of the IP Management Board (WP8), focusing on the evaluation of intellectual property arising from the project. She also contributes to the communication, dissemination and valorisation of results (WP7).
Agnese Tadi
Agnese Tadi is a Biologist with a Master's Degree in Medical Biotechnology for Diagnostics and Therapy. Her current research is focused on Validation of BactEradiX nanoplatform for biofilm eradication. The aim of the project, is comprehensively evaluate the biocompatibility of this antimicrobial nanomaterial and its constituents in order to verify its capability to interact, penetrate and destabilize the biofilm with Z-DNA targeting PNA and subsequently release anti-gene PNA by lipid disassembling/degradation. Her work will be focalised on WP2, WP5, WP6 and WP7.
All the Consortium
